Table 4.

Results of the univariable and multivariable meta-regression on the incidence of high-grade ICANS.

		High-grade neurotoxicity
		Univariable meta-regression		Multivariable meta-regression
Variable		Odds ratio (95% CI)	P -value	Odds ratio (95% CI)	P -value
Drug agents	Anti-BCMA	REF		REF
	Anti-CD22	0.3 (0.01–4.8)	0.356	0.3 (0.01–4.7)	0.351
	Anti-CD19	4.9 (1.6–14.7)	0.006	4.6 (1.5–13.7)	0.008
Disease	Multiple myeloma	REF
	Lymphoma	3.9 (1.3–11.8)	0.017
	Leukemia	5.9 (1.8–19.0)	0.003
Phase	1	REF		REF
	2	1.1 (0.5–2.4)	0.831	1.2 (0.6–2.5)	0.687
Number of agents	Single agent	REF
	Combination of agents	0.5 (0.2–1.3)	0.158
Co-stimulatory domain	4-1BB	REF
	CD28	1.0 (0.4–2.4)	0.992
	Combination	1.0 (0.2–5.9)	0.966
CNS involvement	Included	REF
	Included without actual involvement	1.0 (0.2–5.1)	0.997
	Excluded	0.7 (0.3–1.6)	0.366
	No information	0.4 (0.1–1.0)	0.048